Home › Cancro al rene (carcinoma a cellule renali) › California › Los Angeles
Studi clinici su Cancro al rene (carcinoma a cellule renali) a Los Angeles, CA
20 studi su Cancro al rene (carcinoma a cellule renali) cercano partecipanti presso sedi a Los Angeles e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
In reclutamentoFase 1
- Cedars-Sinai Medical Center, Los Angeles
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
In reclutamentoFase 2
- Keck Medicine of USC Koreatown, Los Angeles
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
In reclutamentoFase 1/2
- University of Southern California, Los Angeles
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
In reclutamentoFase 2
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
- Cedars-Sinai Medical Center, Los Angeles
TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma
In reclutamentoFase 1/2
- USC Norris Comprehensive Cancer Center, Los Angeles
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
In reclutamentoFase 3
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
- Cedars-Sinai Medical Center, Los Angeles
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
In reclutamentoFase 1
- University of Southern California, Los Angeles
- Cedars-Sanai Medical Center - Samuel Oschin Comprehensive Cancer, Los Angeles
- Cedars-Sanai Medical Center, Los Angeles
Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial
In reclutamentoFase 1/2
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
In reclutamentoFase 1/2
- USC/Norris Comprehensive Cancer Center, Los Angeles
A Study of MGC026 in Participants With Advanced Solid Tumors
In reclutamentoFase 1
- The Angeles Clinic and Research Institute, Los Angeles
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
In reclutamentoFase 3
- USC Norris Comprehensive Cancer Center ( Site 0126), Los Angeles
- Cedars-Sinai Medical Center ( Site 0112), Los Angeles
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
In reclutamentoFase 1/2
- California Research Institute, Los Angeles
- Valkyrie Clinical Trials, Los Angeles
An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer
In reclutamentoFase 2
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
In reclutamentoFase 1
- Start Lacn, Los Angeles
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
In reclutamentoFase 1
- University of Southern California, Los Angeles
- Cedars-Sinai Medical Center, Los Angeles
- UCLA Department of Medicine, Los Angeles
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
In reclutamento
- Oncology Institute for Hope and Innovation, Los Angeles
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
In reclutamentoFase 1/2
- USC Norris Comprehensive Cancer Center, Los Angeles
A Study of VET3-TGI in Patients With Solid Tumors
In reclutamentoFase 1
- USC/Norris Comprehensive Cancer Center, Los Angeles
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
In reclutamentoFase 1/2
- UCLA Medical Center, Los Angeles
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
In reclutamentoFase 3
- Keck Medicine of USC Koreatown, Los Angeles
- Los Angeles County-USC Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
- e altri 2
Studi su Cancro al rene (carcinoma a cellule renali) in altre città
- Houston, TX35 studi
- New York City, NY27 studi
- Nashville, TN23 studi
- Dallas, TX23 studi
- St. Louis, MO23 studi
- Boston, MA16 studi
- Baldwin Park, CA16 studi
- Pittsburgh, PA15 studi
- Philadelphia, PA15 studi
- Queens, NY15 studi
- Cleveland, OH14 studi
- Rochester, MN14 studi
Altri studi a Los Angeles
- Cancro del polmone non a piccole cellule87 studi
- Cancro (tutti i tipi)74 studi
- Cancro al seno73 studi
- Cancro alla prostata61 studi
- Cancro colorettale59 studi
- Cancro metastatico57 studi
- Cancro ovarico50 studi
- Cancro ai polmoni45 studi
- Carcinoma a cellule squamose della testa e del collo42 studi
- Cancro pancreatico35 studi
- Cancro dell'endometrio34 studi
- Melanoma34 studi
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.